To facilitate biosimilar uptake, several mechanisms aimed at reducing the acquisition cost of biosim...
Read moreHTA bodies and companies within the pharmaceutical industry have been forced to react to unprecedent...
Read moreThis study aimed to assess whether the new process has resulted in changes to outcomes of STAs.
Read moreWhilst many businesses are currently working remotely, up-skilling your workforce through interactiv...
Read moreDifferences in market access and reimbursement processes are an important factor in determining the ...
Read morePharmaceutical companies are incorporating payer / HTA needs into their clinical and commercial laun...
Read moreIn England, to gain a positive recommendation for use within the NHS from NICE, pharmaceutical produ...
Read morePharmaceutical pricing and market access is the crucial challenge for successful product launch toda...
Read moreWhat is the future of precision medicine in the EU? The field of precision medicine is a complex are...
Read moreNICE will continue to offer joint advice with the Medicines and Healthcare products Regulatory Agenc...
Read more